Irritable Bowel Syndrome Treatment Market Trends

Global Irritable Bowel Syndrome Treatment Market Overview

Irritable Bowel Syndrome Treatment Market Size was valued at USD 1.8 billion in 2022. The irritable bowel syndrome treatment market industry is projected to grow from USD 1.94 Billion in 2023 to USD 3.62 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.1% during the forecast period (2023 - 2032).The increase in the geriatric population, the rise in the prevalence of gastrointestinal disorders and diseases such as bowel habit changes and abdominal pain, the upsurge in stress levels, and an unhealthy diet are the key market drivers boosting the irritable bowel syndrome treatment industry share.Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

In October 2023, Teva Pharmaceuticals, the U.S. subsidiary of Teva Pharmaceutical Industries Ltd., and Sanofi announced a partnership to jointly develop and market asset TEV'574. This asset is currently in Phase 2b clinical trials for the treatment of Crohn's disease and ulcerative colitis, both of which are types of inflammatory bowel disease. Sanofi will take the lead in developing the Phase 3 program, and all businesses will share the development costs and the profits and losses in key countries equally. Additional markets will be bound by a royalty agreement. Teva will lead the efforts to bring the product to market in Europe, Israel, and a few additional countries. Sanofi will be responsible for managing the commercialization of the product in North America, Japan, other Asian nations, and globally.

In June 2023, the U.S. FDA granted authorization for LINZESS® (linaclotide) to be used as a once-daily treatment for children between the ages of 6 and 17 who suffer from functional constipation. Ironwood Pharmaceuticals, Inc., a healthcare company specializing on gastrointestinal (GI) conditions, made this news. LINZESS is the sole FDA-approved prescription medicine for functional constipation in this specific group of patients. The FDA granted our supplementary New Drug Application (sNDA) a 6-month priority review earlier this year, surpassing the standard review timetable by four months. AbbVie and Ironwood Pharmaceuticals are the entities in the United States that have the responsibility for the development and commercialization of LINZESS. In this pivotal trial, Linacetide exhibited a statistically significant and clinically meaningful enhancement in the primary outcome of the rate of spontaneous bowel movements (SBMs) each week during a 12-week period, as compared to a placebo. LINZESS 72mcg is officially approved by the FDA for the treatment of functional constipation in pediatric patients aged 6 to 17 years old. This approval builds upon the existing comprehensive coverage of the brand's formulary.

Irritable Bowel Syndrome Treatment Market Trends

• Growing incidence of irritable bowel syndrome and related diseases to drive market growth

Irritable bowel syndrome (IBS) is a common chronic gastrointestinal condition that causes bowel irregularities and abdominal pain. The condition is also called spastic colitis, irritable colitis, mucous colitis, and irritable colon. Abdominal pain, constipation, diarrhea, and cramping are all symptoms of irritable bowel syndrome. Irritable bowel syndrome prevalence is increasing significantly across all regional health systems. According to data published by the International Foundation for Gastrointestinal Disorders, approximately 40% of all IBS patients have mild IBS, approximately 35% have moderate IBS, and approximately 25% have severe IBS. Many people are unaware of IBS symptoms.

The efficient management of irritable bowel syndrome has increased the use of different medical drug types, such as anti-diarrheal drugs and alosetron, as metrics for irritable bowel syndrome treatment other than traditional therapeutic means. It has consequently led to higher irritable bowel syndrome treatment market CAGR growth. Food allergies, early gastroenteritis, sporadic colon movements, abnormal serotonin composition in the colon, and mild celiac disease are all risk factors for IBS. These factors are expected to accelerate the prevalence of IBS. For example, according to a report conducted on NCBI in 2019, IBS is predicted to affect 10% to 16% of the US population each year. The staggering prevalence of IBS is anticipated to propel the irritable bowel syndrome treatment market revenue over the projected timeline.

Irritable Bowel Syndrome Treatment Market Segment Insights

Irritable Bowel Syndrome Treatment Type Insights

Based on type, the irritable bowel syndrome treatment market segmentation includes IBS-D, IBS-C, and IBS-M. The IBS-M segment held the majority share in 2022, contributing to around ~46-48% of the irritable bowel syndrome treatment market revenue. The demand for medications that can treat the combined symptoms of constipation and diarrhea is anticipated to increase owing to the rising prevalence of IBS among men and women. IBS is more common in the elderly population. IBS-M shares symptoms such as constipation (IBS-C) and diarrhea (IBS-D). The primary distinction with IBS-M is the alternation of these symptoms. As a result, demand for prescription drugs to treat mixed IBS-M is expected to rise significantly over the forecast period. Linzess/Constella was the market trend in irritable bowel syndrome treatment in 2022, owing to increasing product acceptability in important markets such as the United States, India, Germany, the United Kingdom, Italy, Spain, and Japan.

April 2022:Ardelyx, a biopharmaceutical company, has introduced IBSRELA, the first and only NHE3 inhibitor for irritable bowel syndrome treatment with constipation (IBS-C) in adults. IBSRELA is the first US FDA-approved irritable bowel syndrome treatment product for Ardelyx.

Irritable Bowel Syndrome Treatment Drug Type Insights

Drug types have bifurcated the irritable bowel syndrome treatment market data into lubiprostone, linaclotide, rifaximin, eluxadoline, and alosetron. The linaclotide segment dominated the market in 2022 and is projected to be the faster-growing segment over the forecasting period 2022-2030. The segment's growth is attributed to increased production of generic linaclotide and higher market consolidation for developing and commercializing linaclotide to treat IBS. Linaclotide is in high demand due to its efficacy in treating chronic constipation and irritable bowel syndrome with constipation (IBS-C), previously unmet by traditional approaches. Its higher adoption rate will likely increase demand over the projected period. The effectiveness of the linaclotide drug in comparison to similar drugs on the market drives overall irritable bowel syndrome treatment growth.

January 2019: AstraZeneca announced that its partner Ironwood Pharmaceuticals Inc had obtained marketing authorization from China's National Medical Products Administration (NMPA) for Linaclotide (Linzess), employed to treat adult patients with constipation-related irritable bowel syndrome treatment.

Irritable Bowel Syndrome Treatment End-User Insights

The irritable bowel syndrome treatment industry has been segmented based on end-user into hospitals, clinics, research laboratories, and others. Hospitals held the most prominent segment share in 2022. The availability of drugs for treating irritable bowel syndrome, as well as the ease and accessibility of dispensing, contribute to the growing demand from hospitals. The rise in the prevalence of gastrointestinal disorders and irritable bowel syndrome has resulted in increased government participation in irritable bowel syndrome treatment from hospitals. For instance, in the US, 167,000 hospitalizations and 300 pediatric fatalities yearly are attributed to diarrheal illnesses.

Figure 2: Irritable Bowel Syndrome Treatment Market by End-User, 2022 & 2030 (USD Billion)

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

Irritable Bowel Syndrome Treatment Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Irritable Bowel Syndrome Treatment market was worth USD 0.82 billion in 2022 and is projected to grow at a significant CAGR over the study period due to the existence of key market players, growing prevalence of chronic constipation, well-established healthcare systems, increased patient awareness, and a strong presence of novel products. Additionally, the United States dominates the market in North America due to various factors, including many companies presence that produces constipation drugs. Moreover, several market participants are launching new irritable bowel syndrome treatment products, contributing to the region's growth. For instance, IBSRELA (tenapanor), a first-in-class therapy for treating adults with irritable bowel syndrome with constipation (IBS-C), was made commercially available in Canada by Knight Therapeutics Inc in March 2021. Under a license agreement with Ardelyx Inc, the company has the exclusive right to commercialize IBSRELA in Canada.

Further, the major countries studied in the market report are the U.S., Germany, Canada, France, the UK, Spain, Italy, Japan, India, Australia, China, South Korea, and Brazil.

Figure 2: IRRITABLE BOWEL SYNDROME TREATMENT MARKET SHARE BY REGION 2022 (%)

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

The European irritable bowel syndrome treatment market holds the second-largest market share due to a sizable target population and the increasing commercialization of IBS products in the region. Increasing regional efforts to spread awareness of the condition will also accelerate market expansion. Numerous businesses produce products for irritable bowel syndrome. Additionally, the regional businesses promote awareness of the signs, causes, signs, and treatments of irritable bowel syndrome. The International Foundation for Gastrointestinal Disorders estimates that between 2.4 and 3.5 million people in the United Kingdom seek treatment for irritable bowel syndrome each year. Further, the German irritable bowel syndrome treatment market held the largest market share, and the UK irritable bowel syndrome treatment market was the fastest-growing market in the European region.

The Asia-Pacific Irritable Bowel Syndrome Treatment Market is expected to grow at the fastest CAGR from 2022 to 2030. Asia-Pacific offers lucrative opportunities for key players in the irritable bowel syndrome treatment market, with rising awareness of irritable bowel syndrome treatment and increased adoption of irritable bowel syndrome treatment products. Moreover, advancements in healthcare infrastructure, an increase in the number of health facilities equipped with advanced medical centers, a growing R&D sector, an increase in healthcare reforms, and technological developments in the healthcare field all contribute to market growth. Other factors expected to drive the growth of the Asia-Pacific irritable bowel syndrome treatment market include the increased focus of leading manufacturers on broadening their geographical reach in emerging regional countries to grab high growth opportunities within the market, a large population base, and rising disposable incomes. Furthermore, China’s irritable bowel syndrome treatment market held the largest market share, and the Indian irritable bowel syndrome treatment market was the fastest-growing market in the Asia-Pacific region.

Irritable Bowel Syndrome Treatment Key Market Players & Competitive Insights

The irritable bowel syndrome treatment industry has recently delivered prescription medication with some of the most substantial advantages. The irritable bowel syndrome treatment market’s major players, such as Allergan Inc, Synergy Pharmaceuticals, Ardelyx, Abbott, and others, are working to increase industry demand by investing in IBS drug research and development activities. Competing companies in the irritable bowel syndrome treatment industry must offer drugs to expand and sustain in a highly competitive and rising competitive landscape.

With significant market developments like introducing new products, contractual arrangements, mergers & acquisitions, increased drug R&D investments, and collaborative projects with other organizations, market players are also undertaking various strategic initiatives to expand their footprint. Manufacturing drugs domestically to cut operating costs is one of the leading business strategies manufacturers use in the irritable bowel syndrome treatment industry to benefit customers and expand the marketplace.

Ferring Pharmaceuticals is a multinational biopharmaceutical company headquartered in Switzerland specializing in reproductive health, maternal health, gastroenterology, and urology. The business develops and sells medications for bedwetting, prostate cancer treatment, irritable bowel syndrome treatment, nycturia, safe delivery, and gastrointestinal and growth disorders. Ferring B.V., a biopharmaceutical company, announced in June 2022 that it had signed a strategic partnership with I-MAB Biopharma Co., Ltd, an innovation-driven biopharmaceutical company, to develop further olamkicept, a selective interleukin-6 (IL-6) trans-signaling antagonist for inflammatory bowel disease (IBD) and related inflammatory conditions.

Also, Bausch Health Companies Inc is a multinational specialty pharmaceutical corporation headquartered in Laval, Quebec. It creates, produces, and sells branded generic medications and pharmaceutical products, primarily for eye health, neurology, gastrointestinal disorders, irritable bowel syndrome treatment, and skin conditions. Bausch Health Companies Inc introduced GastroHub for advanced practice providers in March 2021. It is a website for nurse practitioners and medical assistants that provides information on treating IBS-D and HE.

Key Companies in the irritable bowel syndrome treatment market include

• 
  

  Valeant Pharmaceuticals International

  
  


• 
  

  Allergan Inc

  
  


• 
  

  Astellas Pharma

  
  


• 
  

  Lexicon Pharmaceuticals

  
  


• 
  

  Nestle Health Science

  
  


• 
  

  Synergy Pharmaceuticals Inc

  
  


• 
  

  Ironwood Pharmaceuticals

  
  


• 
  

  Ardelyx

  
  


• 
  

  Mallinckrodt

  
  


• 
  

  Abbott

  
  

Irritable Bowel Syndrome Treatment Industry Developments

March 2022:Indegene, a provider of technology-led healthcare solutions, and metaMe Health, the developer of Regulora and a Prescription Digital Therapeutics (PDT) company, collaborated to bring Regulora to market for the treatment of abdominal pain caused by irritable bowel syndrome (IBS).

March 2021:Abbott and the Nutrition Society of India collaborated to raise awareness among GI patients by introducing India-specific diagnostic and therapeutic dietary recommendations. Functional constipation, chronic pancreatitis, peptic ulcers, and irritable bowel syndrome are all GI disorders.

January 2020:OrphoMed Inc began a Phase II response-adaptive medical study (PREVAIL trial) of ORP-101 to diagnose irritable bowel syndrome with diarrhea (IBS-D). ORP-101 is a novel chemical entity designed to produce a sizeable stable molecule with partial agonist and complete -antagonist receptor pharmacology.

Irritable Bowel Syndrome Treatment Market Segmentation

Irritable Bowel Syndrome Treatment Type Outlook

• 
  

  IBS-D

  
  


• 
  

  IBS-C

  
  


• 
  

  IBS-M

  
  

Irritable Bowel Syndrome Treatment Drug Type Outlook

• 
  

  Lubiprostone

  
  


• 
  

  Linaclotide

  
  


• 
  

  Rifaximin

  
  


• 
  

  Eluxadoline

  
  


• 
  

  Alosetron

  
  

Irritable Bowel Syndrome Treatment End-User Outlook

• 
  

  Hospitals

  
  


• 
  

  Clinics

  
  


• 
  

  Research Laboratories

  
  


• 
  

  Others

  
  

Irritable Bowel Syndrome Treatment Regional Outlook

• 
  

  North America

  
  

• 
  
  
  
  • 
    

    US

    
    
  
  
  • 
    

    Canada

    
    
  
  
  
  

• 
  

  Europe

  
  

• 
  
  
  
  • 
    

    Germany

    
    
  
  
  • 
    

    France

    
    
  
  
  • 
    

    UK

    
    
  
  
  • 
    

    Italy

    
    
  
  
  • 
    

    Spain

    
    
  
  
  • 
    

    Rest of Europe

    
    
  
  
  
  

• 
  

  Asia-Pacific

  
  

• 
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  

• 
  

  Rest of the World

  
  

• 
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America